Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
During the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs, Capitini emphasized that all cancers should eventually find benefit in immunotherapy. With expansion in renal cell carcinoma (RCC), lung cancer and head and neck cancer, that change may be underway.
MLB VP Reveals Cancer Diagnosis, Jaxon-Smith Njigba Raises Awareness for Cancer Foundation and More
December 8th 2023As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer photo, here is what’s happening in the oncology space this week.
Read More
Zanzalintinib Is Promising in Clear-Cell Advanced Renal Cell Carcinoma
November 14th 2023Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.
Read More